News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Vertex Pharmaceuticals Incorporated Hepatitis C Drug Meets Study Goal
August 1, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass. - Vertex Pharmaceuticals Inc. said late Thursday its hepatitis C drug candidate telaprevir was both safe and prompted a response in patients during a midstage study.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Obesity
Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership
August 14, 2025
·
1 min read
·
Dan Samorodnitsky
Pipeline
Schrödinger Cans Early-Stage Blood Cancer Drug After Two Patient Deaths
August 14, 2025
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
CytomX Reports Treatment-Related Patient Death in Phase I Colorectal Cancer Study
August 14, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Vedanta Downsizes by 20% After Phase II Stumble in Ulcerative Colitis
August 14, 2025
·
2 min read
·
Tristan Manalac
